Bevacizumab in renal-cell cancer.
Guru
G
Sonpavde
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D018450:Disease Progression; D016228:Endothelial Growth Factors / Q000037:antagonists & inhibitors*; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy*; D008207:Lymphatic Metastasis; D016032:Randomized Controlled Trials as Topic
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D016228:Endothelial Growth Factors; D000068258:Bevacizumab